The Angina Pectoris Therapeutics Market is Expected to Show Moderate Growth Up to 2018

Monday 12 March 2012, Amsterdam

The report is an essential source of information and analysis on the global angina pectoris therapeutics market and identifies the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global angina pectoris therapeutics sector.

The Angina Pectoris Therapeutics Market is Expected to Show Moderate Growth Up to 2018

They has estimated the global angina pectoris therapeutics market to be worth $9,655.4m in 2010. It is expected to grow to $12,707.4m by 2018 at a compound annual growth rate (CAGR) of 3.5%. This growth can be primarily attributed to the rise in the number of patients undergoing treatment for angina pectoris and the expected approval of novel therapies such as Generx and varespladib, which are currently in late stage clinical development. However, if approved, these products are expected to be marketed at a premium price by their innovator companies when compared to other treatment options for angina. The reason why the launch of such products is at premium prices is attributed to the novel mechanism of action of these products which leads to a marked improvement in efficacy and safety over the currently marketed products. As a result the market penetration of these products is expected to remain low, limiting the growth rate of the angina pectoris therapeutics market. The forecast period will also witness patent expiries of major marketed products such as Lipitor (atorvastatin) in 2011, Aggrastat (tirofiban) in 2012, Angiomax/Angiox (bivalirudin) in 2015 in Europe and Crestor (rosuvastatin) in 2016. Such patent expiry of the major marketed products will attract generic versions of these drugs to the market. Therefore the angina pectoris therapeutics market is expected to witness moderate growth with a significant number of generics playing a major role in the forecasted period, which is similar to the present market scenario.

See figure: Angina Pectoris Therapeutics Market, Global, Revenue ($m), 2005 - 2018

Current Competition in the Angina Pectoris Therapeutics Market is Weak

They assessed the current competitive landscape for angina pectoris drugs and found that competition is weak. All the available treatment options are moderately successful in meeting the market demand. Although the market has various treatment options available, none of them is able to manage angina pectoris adequately. The products currently available in the market are associated with average efficacy and safety profiles.

In addition,the current treatment options offer poor quality of life due to their lack of efficacy in reducing cardiovascular events and mortality. As the products currently in the market do not serve the unmet need, the market continues to offer opportunities for products in the pipeline with novel mechanism of action and disease modifying characteristics. The unmet need in the angina pectoris therapeutics market is considered to be significant and can be fulfilled by technologically advanced products with improved safety and efficacy profiles.

The Strong Pipeline with Novel Therapies is Expected to Increase the Competition in the Angina Pectoris Therapeutics Market

The research indicates that the angina pectoris therapeutics market pipeline is strong. There are 16 molecules in the pipeline across various phases of clinical development. An analysis concludes that out of the 16 molecules in the pipeline, twelve molecules are first-in-class based on their unique or novel mechanism of action. Within the late stage of clinical development (Phase III), four molecules are considered to be of commercial importance to the market and are expected to have an impact in the forecast period. These are Generx, varespladib, rivaroxaban and otamixaban which are expected to influence the market growth within the forecast period, following their approval and subsequent launch.

The first-in-class molecules in the angina pectoris therapeutics pipeline such as Generx and omecamtiv have great potential to increase the exercise tolerance test (ETT) time, reduce the frequency of angina episodes, to prolong the time for coronary events and to provide increased quality of life. These products are expected to meet the unmet needs in the angina pectoris therapeutics market and provide patients and physicians with increased options, ultimately leading to increased competition within the market.

Generics will Continue to Dominate the Angina Pectoris Therapeutics Market within the Forecast Period

They found that most of the treatment options currently available in the angina pectoris therapeutics market are generics. The forecast period will also witness patent expiries of major marketed products leading to the entry of generic versions of the drugs. Patents for drugs with high sales in terms of value, which include Pfizer’s blockbuster drug Lipitor, Aggrastat, Angiomax and Crestor are scheduled to expire within the forecast period.

The genericization of these blockbuster drugs will hinder the penetration of novel therapies into the market leading to moderate and steady growth. To conclude, the angina pectoris therapeutics market will continue to be dominated by generics during the forecast period.